Jung, Sung Youb,Kwon, Se Chang,Jang, Myung Hyun,Choi, In Young,Kim, Jin-Sun,Lee, Sang Hyun
申请号：
NZ73165713
公开号：
NZ731657A
申请日:
2013.07.25
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
The present invention relates to the use of an oxyntomodulin derivative conjugate in the preparation of a medicament for preventing or treating hyperlipidemia, fatty liver disease or atherosclerosis, wherein the oxyntomodulin derivative conjugate comprises； an oxyntomodulin derivative comprising the amino acid sequence of any one of SEQ ID NOs: 23, 27, 28, 32, 33, or 34, an immunoglobulin Fc region, and a non-peptidyl polymer, the non-peptidyl polymer comprising polyethylene glycol, polypropylene glycol, an ethylene glycol/propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polyvinyl ethyl ether, PLA (polylactic acid), PLGA (polylactic-glycolic acid), a lipid polymer, hyaluronic acid, or combinations thereof, and wherein the non-peptidyl polymer covalently links the oxyntomodulin derivative and the immunoglobulin Fc region； wherein the oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used in the manufacture of a medicament for the treatment of hyperlipidemia and related diseases.
